Nevertheless, the genetic evidence is in line with our pharmacological results and confirms the synergy of PLK1 and FGFR inhibition in KRAS‐mutant lung and pancreatic cancer cells. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.